3. Verbeurgt, P., T. Mamiya and J. Oesterheld (2014). "How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping." Pharmacogenomics 15(5): 655-665.
Harmonized PGx Data
How does 2bPrecise help clinicians make better medication decisions? An intuitive dashboard delivers critical information about patients’ ability to metabolize current medications – and triggers alerts about potentially devastating adverse reactions. And once the PGx test has been performed, the data can be re-interrogated and applied to clinical decision making throughout the patients’ lifetime.
Better Decisions, Better Results
Point of Care Results
Test results at the point of care allow providers to discuss current medications with patients in real time.
Which do they metabolize appropriately -- making them safer and more likely to be effective?
Which do they not metabolize well – rendering them ineffective or even harmful?
PGx test results remain consistent throughout the patient’s lifetime. A single test, done now, can be used by doctors as they make decisions for years into the future.
The patient might develop new conditions where different medications need to be prescribed
New medications might become available and providers will be better equipped to decide if they are right for the patient
New discoveries about documented genetic variations may be revealed – which could impact treatment decisions
We enable healthcare organizations to get started with precision medicine anywhere they want – oncology? pediatrics? cardiology? pharmacogenomics?